Navigation Links
Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine

SAN FRANCISCO, April 11, 2007 /PRNewswire-FirstCall/ -- Vical Incorporated today announced that a seasonal influenza vaccine formulated with the company's Vaxfectin(TM) adjuvant generated up to 60-fold higher antibody responses than an unformulated vaccine at the same dose in a recently completed study in mice. Formulation of sanofi pasteur's Fluzone(R) commercial vaccine with Vaxfectin(TM) also allowed a nearly 10-fold reduction in vaccine dose while generating equivalent or better antibody responses compared with unformulated vaccine, even at the lowest doses tested. Alain P. Rolland, Pharm.D., Ph.D., the company's Senior Vice President of Product Development, presented the data at the Drug Delivery 2007 meeting (San Francisco, April 9 - 11).

Vical is developing its own Vaxfectin(TM)-formulated DNA vaccine designed to protect against emerging strains of influenza virus that have the potential to cause a pandemic. In previously reported studies conducted at St. Jude Children's Research Hospital, Vical's lead Vaxfectin(TM)-formulated, DNA vaccine candidate provided 100% protection in mice and ferrets against lethal challenges with a highly pathogenic strain of H5N1 influenza virus. Initial human testing of Vical's influenza DNA vaccine is expected to begin in the second half of 2007.

Vical tested the Vaxfectin(TM) adjuvant with Fluzone(R) seasonal influenza vaccine to evaluate its potential to ease the anticipated shortage of stockpiled pandemic influenza vaccine and the limited global vaccine manufacturing capacity. In separate studies conducted by others, stockpiled sanofi pasteur H5N1 pandemic influenza vaccine with no adjuvant achieved target levels of antibodies in less than half the subjects after two 90 mcg doses -- a total of six times the normal 15 mcg dose of each strain that provides 75% to 90% protection against seasonal influenza.

The new Fluzone(R) study data confirm and expan
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
2. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
3. New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
4. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
5. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
6. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
7. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
8. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
9. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
10. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
11. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:10/22/2014)... CHARLOTTESVILLE, Va. and AUSTIN, ... PhosImmune Inc. and PureMHC LLC today announced they ... to develop novel antibody-based immunotherapies designed to target ... identification of phosphorylated peptides displayed on the surfaces ... These phosphopeptide tumor targets (PTTs), derived from proteins ...
(Date:10/22/2014)... 22, 2014  AcelRx Pharmaceuticals, Inc. (NASDAQ: ... the  IAP310 study have been published in ... peer-reviewed journal with broad, multidisciplinary readership. IAP310 was ... safety and efficacy of Zalviso, also referred to ... the treatment of post-operative pain in patients following ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus Therapeutics ... biopharmaceutical company leading the discovery and development ... that it has demonstrated human proof-of-concept with ... study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR ... hepatitis C virus infection ("HCV").  Interim results ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... 2011 /PRNewswire/ -- PRA, a leading Clinical ... Romania to further strengthen our coverage of the Balkan ... projects in the neighboring Republic of Moldova. ... in Romania, the PRA staff has steadily increased and ...
... Aug. 22, 2011 Reportlinker.com announces ... is available in its catalogue: ... Assessments of Leading Suppliers ... This report provides diagnostic imaging industry ...
Cached Medicine Technology:PRA Opens Office in Romania 2Global MRI Market: Strategic Assessments of Leading Suppliers 2Global MRI Market: Strategic Assessments of Leading Suppliers 3Global MRI Market: Strategic Assessments of Leading Suppliers 4Global MRI Market: Strategic Assessments of Leading Suppliers 5
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 Allegheny ... minimally-invasive procedure that enables physicians to repair a damaged ... The MitraClip system, developed by Abbott ... (MR), a progressive and life-threatening condition in which the ... blood to flow backward from the heart’s left ventricle ...
(Date:10/20/2014)... 2014 ASCNYC (ascnyc.org) is a ... New Yorkers living with HIV/AIDS and other chronic ... recovery and self-sufficiency. Each year, ASCNYC spotlights selected ... through their tireless efforts. , Savills Studley ... has been selected as this year’s honoree for ...
(Date:10/20/2014)... T.E.N., a technology and information security ... William H. Murray, renowned author and industry visionary, ... Award winner. Presented annually, the ISE® Luminary Leadership ... and industry practitioner for his or her distinguished ... security industry. , Formerly with IBM, Murray is ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ovarian ... to think outside the bra. She doesn’t try to hide ... awareness about women’s other lady parts. , "We have won ... color pink and everybody knows what you’re talking about,” Jess-Huff ... has not been won when it comes to gynecologic cancers. ...
(Date:10/20/2014)... 2014 My Clients Plus ( http://www.MyClientsPlus.com ... The new module enables easy administration and routing ... quality care. , This application allows users such as ... attach a to-do item to a specific client, categorize ... up reoccurring reminders for follow-ups. It's designed to ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2
... technology to process the conversion of medical records from microfiche to ... ... 2009 -- Penny Imaging Exchange, Inc. (PIE) has acquired new technology ... form - the DRS Digitizer . With the Obama administration ...
... CHICAGO, April 17 Specialty Underwriters, Alliance, Inc. ... announced today that Glass Lewis & Co., a leading ... WHITE proxy card and do not vote for the nominees ... SUA,s Annual Meeting of Stockholders will be held at 9:00 ...
... Volunteer Week, is April 19 - April 25 ... today praised Pennsylvania,s volunteers for selflessly giving their time ... and urged other citizens to join those important efforts. ... opportunity to thank our volunteers for generously sharing their ...
... Assurance solutions help MEDNAX increase security and simplify ... Corporation , leaders in access governance, provisioning ... implemented the company,s Enterprise Suite to assure access ... 5,000 clinical and administrative employees. MEDNAX is ...
... such study involves effort to improve chemotherapy effectiveness , , FRIDAY, ... research and testing, only a small percentage of cancer agents ... have come up with a way to weed out the ... the marketplace. , The new model, a so-called "phase ...
... South Florida physician Sanford Siegal, D.O., M.D., explains why ... and reveals how to overcome this obstacle to reaching ... Sanford Siegal, Medical Director of Miami, Florida-based weight-loss practice, ... among dieters that the most challenging part of reaching ...
Cached Medicine News:Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 2Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 3Health News:Leading Independent Proxy Advisory Firm Supports Specialty Underwriters' Alliance, Inc. in Its Proxy Contest Against Hallmark Financial Services, Inc. 2Health News:Leading Independent Proxy Advisory Firm Supports Specialty Underwriters' Alliance, Inc. in Its Proxy Contest Against Hallmark Financial Services, Inc. 3Health News:PA Secretary of Health Recognizes Pennsylvania Volunteers; Urges Greater Citizen Involvement 2Health News:MEDNAX National Medical Group(TM) Uses Courion's Enterprise Suite to Automate Identity and Access Management 2Health News:MEDNAX National Medical Group(TM) Uses Courion's Enterprise Suite to Automate Identity and Access Management 3Health News:'Phase 0' Trials Aim to Speed Cancer Drug Development 2Health News:'Phase 0' Trials Aim to Speed Cancer Drug Development 3Health News:Losing the Last Ten Pounds is the Hardest Part of any Diet Confirms Weight-Loss Expert and Author Dr. Sanford Siegal 2
Research Series 2100 Adjustable-volume Pipette,100-1,000 l, single-channel with adjustable-volume setting...
... operations, the Sysmex KX-21N is ideal ... lab testing. This 3-part differential ... Built on the reliable, field proven ... a completely automatic START-UP function and ...
... of pacemakers features several of the ... in today's worldwide pacing market. Offering ... and diagnostic information, the system builds ... pacemakers platform. , ,It incorporates ...
... of pacemakers features several of the ... in today's worldwide pacing market. Offering ... and diagnostic information, the system builds ... pacemakers platform. , ,It incorporates ...
Medicine Products: